Beautiful Virgin Islands

Tuesday, Jun 03, 2025

AstraZeneca shares fall after efficacy findings for Covid-19 vaccine

AstraZeneca shares fall after efficacy findings for Covid-19 vaccine

Analysts say ‘lower efficacy for higher dose’ needs explaining, as results below those of rivals
AstraZeneca shares fell after the drugmaker announced efficacy results for its Covid-19 vaccine that were below those reported by rivals Pfizer/BioNTech and Moderna. The shares ended the day 3.8% lower at £80.

Results from the phase 3 trial showed the vaccine developed with the University of Oxford can protect 70.4% of people from becoming ill and, in a surprise result, up to 90% if a lower first dose is used.

This is lower than the 95% efficacy reported for vaccines developed by the US drugmaker Pfizer and the German biotech BioNTech, and the US biotech Moderna. Analysts said the AstraZeneca/Oxford results left some unanswered questions.

Maxim Jacobs, of the investment research firm Edison Group, said: “It’s not normal for there to be lower efficacy for a higher dose, it can happen but it’s rare. There are some potential explanations, such as the vector immune response, but it’s hard to know without more data.”

James Bevan, the chief investment officer at the fund manager CCLA, told Sky News the efficacy data had been “rather less than had been anticipated by the market”.

AstraZeneca, which is Britain’s biggest pharmaceutical firm, also reiterated that it would not profit from the vaccine during the current pandemic – until at least July – by pricing “at cost”, about $3 (£2.25) to $5 a dose. This is far below Pfizer’s $19.50 and Moderna’s $25 to $37 a dose.

Neil Wilson, the chief market analyst at the trading platform Markets.com, said: “AstraZeneca shares have had a very good run this year so there is always a bit of ‘sell the news’ to this kind of thing unless it is better than expected.”

The shares slipped further after an analyst at the US investment bank SVB Leerink, Geoffrey Porges, cast doubt over whether the vaccine would be licensed in the US. Porges argued that the design of the studies did not meet the norms of the Food and Drug Administration for the representation of minorities, severe cases, previously infected individuals and the elderly.

In response, Ruud Dobber, the head of AstraZeneca’s biopharmaceuticals division, told Bloomberg TV: “In the US, we are running a trial with more than 30,000 participants, so let’s be patient to see how the FDA will react before making such harsh statements.”

Emily Field, the head of European pharmaceutical research at Barclays bank, said with the trial results out of the way, investors could concentrate on AstraZeneca’s strengths such as cancer treatment, via its oncology unit. “This will allow investor focus to return to Astra’s innovative oncology and other programmes and the company continues to offer one of the best earnings growth rates across EU pharma,” she said.
Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Dutch government falls as far-right leader Wilders quits coalition
Harvard Urges US to Unfreeze Funds for Public Health Research
Businessman Mauled by Lion at Luxury Namibian Lodge
Researchers Consider New Destinations Beyond the U.S.
53-Year-Old Doctor Claims Biological Age of 23
Trump Struggles to Secure Trade Deals With China and Europe
Russia to Return 6,000 Corpses Under Ukraine Prisoner Swap Deal
Microsoft Lays Off Hundreds More Amid Restructuring
Harvey Weinstein’s Publicist Embraces Notoriety
Macron and Meloni Seek Unity Despite Tensions
Trump Administration Accused of Obstructing Deportation Cases
Newark Mayor Sues Over Arrest at Immigration Facility
Center-Left Candidate Projected to Win South Korean Presidency
Trump’s Tariffs Predicted to Stall Global Economic Growth
South Korea’s President-Elect Expected to Take Softer Line on Trump and North Korea
Trump’s China Strategy Remains a Geopolitical Puzzle
Ukraine Executes Long-Range Drone Strikes on Russian Airbases
Conservative Karol Nawrocki wins Poland’s presidential election
Study Identifies Potential Radicalization Risk Among Over One Million Muslims in Germany
Good news: Annalena Baerbock Elected President of the UN General Assembly
Apple Appeals EU Law Over User Data Sharing Requirements
South Africa: "First Black Bank" Collapses after Being Looted by Owners
Poland will now withdraw from the EU migration pact after pro-Trump nationalist wins Election
"That's Disgusting, Don’t Say It Again": The Trump Joke That Made the President Boil
Trump Cancels NASA Nominee Over Democratic Donations
Paris Saint-Germain's Greatest Triumph Is Football’s Lowest Point
OnlyFans for Sale: From Lockdown Lifeline to Eight-Billion-Dollar Empire
Mayor’s Security Officer Implicated | Shocking New Details Emerge in NYC Kidnapping Case
Hegseth Warns of Potential Chinese Military Action Against Taiwan
OPEC+ Agrees to Increase Oil Output for Third Consecutive Month
Jamie Dimon Warns U.S. Bond Market Faces Pressure from Rising Debt
Turkey Detains Istanbul Officials Amid Anti-Corruption Crackdown
Taylor Swift Gains Ownership of Her First Six Albums
Bangkok Ranked World's Top City for Remote Work in 2025
Satirical Sketch Sparks Political Spouse Feud in South Korea
Indonesia Quarry Collapse Leaves Multiple Dead and Missing
South Korean Election Video Pulled Amid Misogyny Outcry
Asian Economies Shift Away from US Dollar Amid Trade Tensions
Netflix Investigates Allegations of On-Set Mistreatment in K-Drama Production
US Defence Chief Reaffirms Strong Ties with Singapore Amid Regional Tensions
Vietnam Faces Strategic Dilemma Over China's Mekong River Projects
Malaysia's First AI Preacher Sparks Debate on Islamic Principles
White House Press Secretary Criticizes Harvard Funding, Advocates for Vocational Training
France to Implement Nationwide Smoking Ban in Outdoor Spaces Frequented by Children
Meta and Anduril Collaborate on AI-Driven Military Augmented Reality Systems
Russia's Fossil Fuel Revenues Approach €900 Billion Since Ukraine Invasion
U.S. Justice Department Reduces American Bar Association's Role in Judicial Nominations
U.S. Department of Energy Unveils 'Doudna' Supercomputer to Advance AI Research
U.S. SEC Dismisses Lawsuit Against Binance Amid Regulatory Shift
Alcohol Industry Faces Increased Scrutiny Amid Health Concerns
×